JPMorgan raised the firm’s price target on Cardinal Health to $117 from $112 and keeps a Neutral rating on the shares. With all three healthcare distributors trading at or near all-time highs, the companies are entering Q4 earnings “very well owned,” the analyst tells investors in a research note. “Consistent with prior quarters, while the bar is undoubtedly high, the fundamental picture for each appears strong entering the quarter,” writes the firm. JPMorgan believes the group should deliver solid results and updated price targets to reflect a continued favorable backdrop for distributors entering 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CAH:
- Cardinal Health price target raised to $128 from $126 at Baird
- Cardinal Health affirms long-term financial targets
- Cardinal Health raises FY24 EPS view to $6.75-$7.00 from $6.50-$6.75
- Early notable gainers among liquid option names on January 3rd
- Barclays starts healthcare technology, distribution with Neutral view